CTOs on the Move

Makindus

www.makindus.com

 
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.makindus.com
  • 3805 Old Easton Road
    Doylestown, PA USA 18902
  • Phone: 267.291.4912

Executives

Name Title Contact Details

Similar Companies

Ginkgo Bioworks

At Ginkgo Bioworks we are expanding the role of biology in our world.Nature`s biodiversity holds answers to challenges in health, energy, food, materials, and more. Organism Engineers at Ginkgo learn from Nature to develop new organisms that replace technology with biology.

Puget Sound Kidney Centers

Puget Sound Kidney Centers is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Perseus

Perseus is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radiology Associates of Hollywood

Radiology Associates of Hollywood is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Effector

Effector Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby information in genetic sequences is used to direct synthesis of proteins. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses. In cancer, the tightly controlled translation of specific proteins becomes dysregulated, leading to malignancy characterized by uncontrolled growth, immune evasion and metastases. eFFECTOR believes that its therapeutic approach can restore the translational control of processes which tumors have hijacked for their benefit, while preserving normal cell function.